Advertisement

 

 

Chemotherapeutics of visceral leishmaniasis: present and future developments.

Chemotherapeutics of visceral leishmaniasis: present and future developments.
Author Information (click to view)

Sundar S, Singh A,


Sundar S, Singh A, (click to view)

Sundar S, Singh A,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Parasitology 2017 12 07() 1-7 doi 10.1017/S0031182017002116

Abstract

Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

Submit a Comment

Your email address will not be published. Required fields are marked *

twenty − three =

[ HIDE/SHOW ]